RESUMO
Renal cell carcinoma (RCC) is not sensitive to conventional radiotherapy and chemotherapy, and the effectiveness rate of molecular targeted therapy is low. Therefore, it is urgent to identify new treatment methods. Recently, adoptive Tcell therapy has provided a new option for cancer treatment. Furthermore, lowdose chemotherapy not only has no evident side effects and inhibitory effects on the human immune system, but can also enhance the immune activity of some effector cells. Therefore, it is surmised that the combination of different mechanisms of chemotherapy and immunotherapy could be a new treatment concept. In the present study, the effects of lowdose chemotherapy combined with T cells in the treatment of renal cell carcinoma were explored using cytotoxicity assays, enzymelinked immunosorbent assay (ELISA), western blot analysis and flow cytometric analysis. The results revealed that lowdose chemotherapy and T cells had synergistic effects on tumor cell elimination in vitro. The transforming growth factor (TGF)ß signaling pathway may be involved in the inhibition of Tcell functions. The targeted inhibition of TGFß signals may be a promising therapeutic strategy for the treatment of renal cancer. The present results provided a novel strategy for the combination of lowdose chemotherapy and T cells to enhance the therapeutic efficacy of RCC treatment.
